Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paliperidone Palmitate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 12/20 | 0.71 |
| ▸ | HTR2A known ✓ | P28223 | 11/20 | 0.71 |
| ▸ | HTR7 | P34969 | 4/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.71 |
| ▸ | DRD1 | P21728 | 2/20 | 0.71 |
| ▸ | DRD4 | P21917 | 2/20 | 0.71 |
| ▸ | DRD5 | P21918 | 2/20 | 0.71 |
| ▸ | HTR1D | P28221 | 2/20 | 0.71 |
| ▸ | HTR1B | P28222 | 2/20 | 0.71 |
| ▸ | HTR2C | P28335 | 2/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.71 |
| ▸ | HRH1 | P35367 | 2/20 | 0.71 |
| ▸ | DRD3 | P35462 | 2/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.71 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 3/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343354 | 1.00 | DRD2 (0.71) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| Paliperidone Palmitate SCHEMBL1871384 | 1.00 | DRD2 (0.71) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| SCHEMBL4273254 | 1.00 | DRD2 (0.71) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| SCHEMBL4263975 | 1.00 | DRD2 (0.71) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| Paliperidone Palmitate SCHEMBL18131955 | 1.00 | DRD2 (0.71) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| SCHEMBL24018542 | 1.00 | DRD2 (0.71) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| Hydrochloric Acid SCHEMBL9196896 | 0.99 | DRD2 (0.70) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| SCHEMBL14378106 | 0.96 | DRD2 (0.66) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| SCHEMBL24465197 | 0.96 | DRD2 (0.66) | DRD2HTR2AHTR7KCNH2ADRA2A | |
| SCHEMBL22633922 | 0.95 | HTR2A (0.71) | DRD2HTR2AHTR7KCNH2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20250057809-A1 | COMPOSITIONS AND METHODS FOR TREATING INDUCED DISORDERS FOLLOWING NON-HEMORRHAGIC CLOSED HEAD INJURY | BOULDER BIOSCIENCE LLC | 2025-02-20 | — | — | US | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | OJAI ENERGETICS PBC | 2024-05-09 | — | — | US | claimed |
| US-20240131005-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY | BOULDER BIOSCIENCE LLC | 2024-04-25 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2023107966-A1 | SALT AND SOLID FORMS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND ANALOGS | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| EP-4188996-A1 | METHOD AND PACKAGE FOR REDUCING THE DEGRADATION OF A DRUG AND/OR EXCIPIENT, E.G. POLYSORBATE STABILIZER, IN A PHARMACEUTICAL PRODUCT | SiO2 Medical Products, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| EP-4168068-A1 | ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES | SiO2 Medical Products, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| US-20220244247-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2022-08-04 | — | — | US | claimed |
| EP-4034205-A1 | MEASURING PARAMETERS ASSOCIATED WITH DRUG ADMINISTRATION AND DRUG ADMINISTRATION DEVICES INCORPORATING SAME | Janssen Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | claimed |
| WO-2022119840-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | OJAI ENERGETICS PBC (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022109619-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220161969-A1 | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-26 | — | — | US | claimed |
| US-11298293-B2 | PECVD coated pharmaceutical packaging | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | DRD2 106/4885HTR2A 37/4885HTR7 18/4885 |
| US-20250057809-A1 | COMPOSITIONS AND METHODS FOR TREATING INDUCED DISORDERS FOLLOWING NON-HEMORRHAGIC CLOSED HEAD INJURY | HTR3C, NOTCH3, S100P | DRD2 739/4885HTR2A 232/4885HTR7 626/4885 |
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | CNR2, CNR1, FAAH | DRD2 481/4885HTR2A 701/4885HTR7 525/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | DRD2 3726/4885HTR2A 2946/4885HTR7 1955/4885 |
| US-20240131005-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY | NOTCH3, C1S, ADAM33 | DRD2 990/4885HTR2A 371/4885HTR7 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.